{"filings":[{"id":101337,"accession_number":"0001213900-26-023022","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CPHI subsidiary acquires patent for $6.93M via stock; issues 12.6M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Hainan Helpson acquires patent for Prinsepia Utilis Esterol Sublingual Tablets from Xiaoyan Zhang.","Transfer price of $6.93M paid as 12.6M restricted shares of CPHI at $0.55 per share.","Patent granted 2018, expires 2038; transferor provides technical services.","Shares issued under Regulation S exemption as offshore transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101336,"accession_number":"0001213900-26-014338","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"China Pharma Holdings acquires topiroxostat nanoemulsion patent for $8.82M in stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Transfer price of $8.82M paid in 12.6M restricted shares at $0.70/share; closing by Feb 20, 2026.","Transferor Xiaoyun Chen to provide technical services including R&D and registration.","Transferor also entitled to 3% of net profit from product after commercial launch.","Patent covers Topiroxostat Nanoemulsion and method; patent expires July 2036."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101335,"accession_number":"0001213900-26-001785","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"China Pharma Holdings shareholders approve reverse stock split up to 1:20 at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected independent directors Gene Michael Bennett, Yingwen Zhang, Baowen Dong (3,500,418+ votes for each).","Approved reverse stock split up to 1:20 (3,500,256 for, 780 against); Board has discretion on timing.","Approved Amendment No.3 to the Amended and Restated 2010 Long-Term Incentive Plan (3,500,258 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117702,"accession_number":"0001213900-25-125299","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"China Pharma subsidiary acquires Ipragliflozin patent for $9.8M in stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Hainan Helpson enters Technology Transfer Agreement to acquire Ipragliflozin tablet patent from Juan Zhang.","Total consideration: $9.8 million paid in 7,000,000 restricted CPHI shares at $1.40 per share.","Transferor to provide technical services including product R&D, registration materials, and application.","Shares issued under Regulation S to non-U.S. person, unregistered and exempt from Securities Act registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117701,"accession_number":"0001213900-25-120129","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"China Pharma subsidiary to acquire captopril microcapsule patent for $6.3M in stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Hainan Helpson subsidiary to receive Captopril microcapsule invention patent and preparation method from Lijie Tang.","Transfer price of $6.3 million paid via 3,500,000 shares of CPHI common stock at $1.80 per share.","Transferor to provide technical services including product R&D, registration materials, and application support.","Shares issued as unregistered securities under Regulation S to a non-U.S. person."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150892,"accession_number":"0001213900-25-029000","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"China Pharma Holdings announces 1-for-10 reverse stock split effective April 15, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio 1:10, effective April 15, 2025, trading to begin on split-adjusted basis.","Board fixed ratio on March 26, 2025; authorized by board October 22, 2024 and stockholders December 22, 2024.","No fractional shares issued; any fractional shares rounded up to whole number.","Stockholders' percentage interest remains unchanged except for fractional share adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186878,"accession_number":"0001213900-24-112685","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"China Pharma rescinds Dec 12 securities purchase agreement; deal void ab initio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Dec 23, 2024, company and an unnamed investor agreed to rescind the Dec 12 securities purchase agreement.","The rescission renders the agreement void from the beginning, as disclosed in prior 8-K filed Dec 13, 2024.","No details on investor or financial impact provided; agreement termination may affect expected capital infusion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186877,"accession_number":"0001213900-24-112658","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"China Pharma shareholders approve reverse stock split at 1:10–1:20; all directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected: Zhilin Li, Heung Mei Tsui (non-independent), Gene Michael Bennett, Yingwen Zhang, Baowen Dong (independent).","Amendment to allow reverse stock split at ratio between 1:10 and 1:20 approved; board retains discretion to effect.","Amendment No.2 to the 2010 Long-Term Incentive Plan approved by shareholders.","Advisory vote on executive compensation approved; frequency set at every three years.","Annual meeting held Dec 22, 2024; quorum of ~52% (9,688,133 shares) of outstanding stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186876,"accession_number":"0001213900-24-108617","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"China Pharma enters into up to $600,000 at-the-market equity offering with institutional investor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SPA signed Dec 12, 2024 for up to $600K of common stock at market price, floor $0.15.","Commitment period Dec 12 – Dec 31, 2024; investor has sole discretion to purchase.","Pricing: lower of prior day close or 5-day avg; repricing if delivery delayed; MFN clause for 30 days.","Investor may return shares within one business day for any reason; no minimum offering amount.","Shares issued under existing S-3 shelf (File 333-276481); proceeds not determinable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219811,"accession_number":"0001213900-24-047965","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"China Pharma extends convertible note maturity to Aug. 2025; minimum monthly payment cut 75%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity date of $557,735 convertible note (Streeterville Capital) extended to August 19, 2025.","Extension fee equal to 2% of outstanding balance added to principal; balance post-fee is $557,735.","Minimum monthly redemption amount reduced from $150,000 to $37,182.33 per month.","Original note principal was $5,250,000 issued November 2021; prior amendment in April 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219810,"accession_number":"0001213900-24-040851","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"China Pharma terminates auditor BF Borgers after SEC denies its practice privilege; appoints Enrome LLP","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["SEC issued Rule 102(e) Order against BF Borgers CPA PC on May 3, 2024, barring it from appearing or practicing before the SEC as an accountant.","China Pharma terminated Borgers as independent auditor on May 7, 2024, with audit committee approval.","Audit committee engaged Enrome LLP as new independent registered public accounting firm, effective May 7, 2024.","No disagreements or reportable events occurred with Borgers during the past two fiscal years through termination.","Borgers' audit reports for FY2023 and FY2022 contained a going-concern qualification but no adverse opinion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}